scholarly journals Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease

Oncotarget ◽  
2018 ◽  
Vol 9 (6) ◽  
pp. 6691-6706 ◽  
Author(s):  
Kyoko Otani ◽  
Dai Inoue ◽  
Kohei Fujikura ◽  
Takahiro Komori ◽  
Shiho Abe-Suzuki ◽  
...  
Keyword(s):  
Castleman’S Disease ◽  
Castleman's Disease ◽  
Multicentric Castleman’S Disease ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Clinicopathologic Study ◽  
Multicentric Castleman's Disease

scholarly journals Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease

RMD Open ◽  
2017 ◽  
Vol 3 (1) ◽  
pp. e000432 ◽  
Author(s):  
Takanori Sasaki ◽  
Mitsuhiro Akiyama ◽  
Yuko Kaneko ◽  
Takehiko Mori ◽  
Hidekata Yasuoka ◽  
...  
Keyword(s):  
Castleman’S Disease ◽  
Castleman's Disease ◽  
Multicentric Castleman’S Disease ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Distinct Features ◽  
Multicentric Castleman's Disease

scholarly journals Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions

2017 ◽  
Vol 56 (9) ◽  
pp. 1095-1099 ◽  
Author(s):  
Hiroki Mochizuki ◽  
Manako Kato ◽  
Takakazu Higuchi ◽  
Ryosuke Koyamada ◽  
Satoru Arai ◽  
...  
Keyword(s):  
Castleman’S Disease ◽  
Skin Lesions ◽  
Castleman's Disease ◽  
Multicentric Castleman’S Disease ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Multicentric Castleman's Disease

Multicentric Castleman’s Disease Mimicking IgG4-Related Disease: A Case Report

2016 ◽  
pp. 293-301
Author(s):  
Eiko Hasegawa ◽  
Akinari Sekine ◽  
Jun-ichi Inenaga ◽  
Takeshi Fujii ◽  
Kenichi Ohashi ◽  
...  
Keyword(s):  
Case Report ◽  
Castleman’S Disease ◽  
Castleman's Disease ◽  
Multicentric Castleman’S Disease ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Multicentric Castleman's Disease

Cutaneous multicentric Castleman's disease mimicking IgG4-related disease

2012 ◽  
Vol 208 (12) ◽  
pp. 746-749 ◽  
Author(s):  
Mai Takeuchi ◽  
Yasuharu Sato ◽  
Katsuyoshi Takata ◽  
Keita Kobayashi ◽  
Kyotaro Ohno ◽  
...  
Keyword(s):  
Castleman’S Disease ◽  
Castleman's Disease ◽  
Multicentric Castleman’S Disease ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Multicentric Castleman's Disease

scholarly journals Membranous nephropathy associated with multicentric Castleman’s disease that was successfully treated with tocilizumab: a case report and review of the literature

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Ryosuke Saiki ◽  
Kan Katayama ◽  
Yosuke Hirabayashi ◽  
Keiko Oda ◽  
Mika Fujimoto ◽  
...  
Keyword(s):  
Membranous Nephropathy ◽  
Periodic Acid ◽  
Castleman’S Disease ◽  
Basement Membranes ◽  
The Body ◽  
Castleman's Disease ◽  
Multicentric Castleman’S Disease ◽  
High Zinc ◽  
Secondary Membranous Nephropathy ◽  
Multicentric Castleman's Disease

Abstract Background Multicentric Castleman’s disease is a life-threatening disorder involving a systemic inflammatory response and multiple organ failure caused by the overproduction of interleukin-6. Although renal complications of Castleman’s disease include AA amyloidosis, thrombotic microangiopathy, and membranoproliferative glomerulonephritis, membranous nephropathy is relatively rare. We experienced a case of secondary membranous nephropathy associated with Castleman’s disease. Case presentation The patient was a 43-year-old Japanese man who had shown a high zinc sulfate value in turbidity test, polyclonal hypergammaglobulinemia, anemia, and proteinuria. A physical examination revealed diffuse lymphadenopathy, an enlarged spleen and papulae of the body trunk. A skin biopsy of a papule on the patient’s back showed plasma cells in the perivascular area and he was diagnosed with multicentric Castleman’s disease, plasma cell variant. Kidney biopsy showed the appearance of bubbling in the glomerular basement membranes in Periodic acid methenamine silver stain and electron microscopy revealed electron dense deposits within and outside the glomerular basement membranes. Since immunofluorescence study showed predominant granular deposition of IgG1 and IgG2, he was diagnosed with secondary membranous nephropathy associated with Castleman’s disease. He was initially treated with prednisolone alone, however his biochemical abnormalities did not improve. After intravenous tocilizumab (700 mg every 2 weeks) was started, his C-reactive protein elevation, anemia, and polyclonal gammopathy improved. Furthermore, his urinary protein level declined from 1.58 g/gCr to 0.13 g/gCr. The prednisolone dose was gradually tapered, then discontinued. He has been stable without a recurrence of proteinuria for more than 6 months. Conclusions Tocilizumab might be a treatment option for secondary membranous nephropathy associated with Castleman’s disease.

Sign in / Sign up

Export Citation Format

Share Document